Gao S, Bao Y, Luo J
Front Surg. 2022; 9:928669.
PMID: 36211291
PMC: 9537756.
DOI: 10.3389/fsurg.2022.928669.
Di Filippo M, Baumann M
Molecules. 2021; 26(22).
PMID: 34834084
PMC: 8625794.
DOI: 10.3390/molecules26226992.
Patcas A, Chis A, Militaru C, Bordea I, Rajnoveanu R, Florin Coza O
Bosn J Basic Med Sci. 2021; 22(1):1-13.
PMID: 34082691
PMC: 8860314.
DOI: 10.17305/bjbms.2021.5859.
Zhao J, Han D, Gao M, Liu M, Feng C, Chen G
Gland Surg. 2020; 9(4):1042-1047.
PMID: 32953613
PMC: 7475359.
DOI: 10.21037/gs-20-355.
Rosenbaum J, Bloom R, Forys J, Hiken J, Armstrong J, Branson J
Mod Pathol. 2018; 31(5):791-808.
PMID: 29327716
DOI: 10.1038/modpathol.2017.181.
Anaplastic Lymphoma Kinase in Cutaneous Malignancies.
Cao S, Nambudiri V
Cancers (Basel). 2017; 9(9).
PMID: 28895885
PMC: 5615338.
DOI: 10.3390/cancers9090123.
[Methodology of Establishing and Identifying NCI-H2228/Crizotinib-resistant Cell Lines In Vitro].
Wu D, Jin G, Zhao D, Zhang Y, Zhao J, Yu H
Zhongguo Fei Ai Za Zhi. 2015; 18(6):330-9.
PMID: 26104888
PMC: 5999905.
DOI: 10.3779/j.issn.1009-3419.2015.06.02.
Preclinical Murine Models for Lung Cancer: Clinical Trial Applications.
Kellar A, Egan C, Morris D
Biomed Res Int. 2015; 2015:621324.
PMID: 26064932
PMC: 4433653.
DOI: 10.1155/2015/621324.
The genesis of tyrosine phosphorylation.
Hunter T
Cold Spring Harb Perspect Biol. 2014; 6(5):a020644.
PMID: 24789824
PMC: 3996475.
DOI: 10.1101/cshperspect.a020644.
Molecular basis of drug resistance: epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors.
Yang S
Tuberc Respir Dis (Seoul). 2013; 75(5):188-98.
PMID: 24348666
PMC: 3861374.
DOI: 10.4046/trd.2013.75.5.188.
An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC).
Quinton C, Ellis P
Cancers (Basel). 2013; 3(3):3506-24.
PMID: 24212966
PMC: 3759208.
DOI: 10.3390/cancers3033506.
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.
Hallberg B, Palmer R
Nat Rev Cancer. 2013; 13(10):685-700.
PMID: 24060861
DOI: 10.1038/nrc3580.
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Tsimberidou A, Iskander N, Hong D, Wheler J, Falchook G, Fu S
Clin Cancer Res. 2012; 18(22):6373-83.
PMID: 22966018
PMC: 4454458.
DOI: 10.1158/1078-0432.CCR-12-1627.
Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population.
Lopes L, Bacchi C
Clinics (Sao Paulo). 2012; 67(7):845-7.
PMID: 22892933
PMC: 3400179.
DOI: 10.6061/clinics/2012(07)23.
ALK-immunoreactive neoplasms.
Minoo P, Wang H
Int J Clin Exp Pathol. 2012; 5(5):397-410.
PMID: 22808292
PMC: 3396068.
Drug repositioning for personalized medicine.
Li Y, Jones S
Genome Med. 2012; 4(3):27.
PMID: 22494857
PMC: 3446277.
DOI: 10.1186/gm326.
ALK and NSCLC: Targeted therapy with ALK inhibitors.
Hallberg B, Palmer R
F1000 Med Rep. 2011; 3:21.
PMID: 22076124
PMC: 3206708.
DOI: 10.3410/M3-21.
[The EML4-ALK fusion gene in NSCLC and the clinical progress].
Wu D, Yu H
Zhongguo Fei Ai Za Zhi. 2011; 14(5):435-40.
PMID: 21569650
PMC: 6000320.
DOI: 10.3779/j.issn.1009-3419.2011.05.10.
All-comers versus enrichment design strategy in phase II trials.
Mandrekar S, Sargent D
J Thorac Oncol. 2011; 6(4):658-60.
PMID: 21532916
PMC: 3082391.
DOI: 10.1097/JTO.0b013e31820e17cb.
